2410 Lillyvale Ave Los Angeles, CA
Grifols is a global healthcare company which, since its foundation in Barcelona in 1909, has been working to improve the health and well-being of people all over the world. Our four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative medicines, solutions and services in more than 100 countries and regions.
As a pioneer in the blood products industry, we are one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma we obtain, we produce essential medicines to treat chronic, rare and sometimes life-threatening diseases. As a recognized leader in transfusion medicine, we have a comprehensive portfolio of solutions designed to ensure safety from donation to transfusion. In addition, we provide hospitals, pharmacies and healthcare professionals with diagnostic tools and services that help improve the detection and treatment of diseases, promoting specialized and efficient care.
Our commitment to science and people drives us day after day to continue innovating and exploring the potential of plasma treatments to respond to the main health challenges facing our society.
With a workforce of over 24,000 employees in more than 30 countries and regions, Grifols is committed to a sustainable business model and is a pioneer in continuous innovation, quality, safety and ethical leadership in the healthcare sector. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
What if your work could improve millions of lives?
117 articles with Grifols
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
Grifols, a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.
4/29/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
- This flagship facility in the principality, the Pyrenees Immunology Research Center (PYIRC), will be one of the few immunology-dedicated research centers in Europe and will serve as an international reference center for the development of treatments for immune system disorders through translational and clinical expertise
Grifols' new commitment of international units (IU) of blood clotting factors for humanitarian aid through the WFH from 2022 to 2030 will more than double its IU donations since 2014, reaching 440 million IU
Grifols, S.A., and announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission on April 9, 2021.
For the smallest and most specialized laboratories, DG Reader Net is designed to work as both a standalone solution or integrated with the Grifols fully automated blood typing technology, the DG Gel system
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
3/11/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
Grifols accelerates its innovation efforts to promote its strategy of long-term growth and continue executing its plan for sustained margin expansion
- Plasmatology aims to become the reference publication for plasma science, bringing together the discipline's knowledge, research and scientific advances that until now lacked a specialized journal
Prestigious healthcare research firm reaffirms PharmacyKeeper Verification as the No. 1 product for Intravenous (IV) Workflow Management
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies
Grifols has been recognized among the world's most sustainable companies by the Dow Jones Sustainability Index, the largest global sustainability index and an international benchmark for socially responsible investors.
The integration of Grifols PharmacyKeeper and clinical education resources from TRC Healthcare will help pharmacy leaders by delivering the most current and relevant evidence-based education available
The trial, part of a collaboration with U.S. government agencies including BARDA, the FDA and the NIH, will evaluate the safety, efficacy and tolerability of the anti-SARS-CoV-2 hyperimmune globulin that, if proven safe and effective, could be a potential treatment for COVID-19
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.
The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma products in Canada - This transaction highlights Grifols' commitment to supporting countries such as Canada to attain self-sufficiency of essential plasma-derived medicines through
9/10/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021
ICU Medical Broadens its Non-PVC/Non-DEHP IV Solutions Portfolio by Entering Long-Term U.S. Distribution Agreement with Grifols for Certain Core IV Solution Products
ICU Medical Inc. announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the United States.